174 related articles for article (PubMed ID: 31882602)
1. Effects of a remote mutation from the contact paratope on the structure of CDR-H3 in the anti-HIV neutralizing antibody PG16.
Kondo HX; Kiribayashi R; Kuroda D; Kohda J; Kugimiya A; Nakano Y; Tsumoto K; Takano Y
Sci Rep; 2019 Dec; 9(1):19840. PubMed ID: 31882602
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
[TBL] [Abstract][Full Text] [Related]
3. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.
Liu L; Wen M; Wang W; Wang S; Yang L; Liu Y; Qian M; Zhang L; Shao Y; Kimata JT; Zhou P
J Virol; 2011 Sep; 85(17):8467-76. PubMed ID: 21715497
[TBL] [Abstract][Full Text] [Related]
4. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.
Pejchal R; Walker LM; Stanfield RL; Phogat SK; Koff WC; Poignard P; Burton DR; Wilson IA
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11483-8. PubMed ID: 20534513
[TBL] [Abstract][Full Text] [Related]
5. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
6. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
7. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
[TBL] [Abstract][Full Text] [Related]
9. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
10. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Doria-Rose NA; Schramm CA; Gorman J; Moore PL; Bhiman JN; DeKosky BJ; Ernandes MJ; Georgiev IS; Kim HJ; Pancera M; Staupe RP; Altae-Tran HR; Bailer RT; Crooks ET; Cupo A; Druz A; Garrett NJ; Hoi KH; Kong R; Louder MK; Longo NS; McKee K; Nonyane M; O'Dell S; Roark RS; Rudicell RS; Schmidt SD; Sheward DJ; Soto C; Wibmer CK; Yang Y; Zhang Z; ; Mullikin JC; Binley JM; Sanders RW; Wilson IA; Moore JP; Ward AB; Georgiou G; Williamson C; Abdool Karim SS; Morris L; Kwong PD; Shapiro L; Mascola JR
Nature; 2014 May; 509(7498):55-62. PubMed ID: 24590074
[TBL] [Abstract][Full Text] [Related]
11. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
[TBL] [Abstract][Full Text] [Related]
12. Repertoire Analysis of Antibody CDR-H3 Loops Suggests Affinity Maturation Does Not Typically Result in Rigidification.
Jeliazkov JR; Sljoka A; Kuroda D; Tsuchimura N; Katoh N; Tsumoto K; Gray JJ
Front Immunol; 2018; 9():413. PubMed ID: 29545810
[TBL] [Abstract][Full Text] [Related]
13. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.
Changela A; Wu X; Yang Y; Zhang B; Zhu J; Nardone GA; O'Dell S; Pancera M; Gorny MK; Phogat S; Robinson JE; Stamatatos L; Zolla-Pazner S; Mascola JR; Kwong PD
J Virol; 2011 Mar; 85(6):2524-35. PubMed ID: 21191009
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.
Chen J; Frey G; Peng H; Rits-Volloch S; Garrity J; Seaman MS; Chen B
J Virol; 2014 Jan; 88(2):1249-58. PubMed ID: 24227838
[TBL] [Abstract][Full Text] [Related]
16. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
[TBL] [Abstract][Full Text] [Related]
17. Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.
Heredia JD; Park J; Choi H; Gill KS; Procko E
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894475
[TBL] [Abstract][Full Text] [Related]
18. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
[TBL] [Abstract][Full Text] [Related]
19. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
[TBL] [Abstract][Full Text] [Related]
20. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.
Persson H; Ye W; Wernimont A; Adams JJ; Koide A; Koide S; Lam R; Sidhu SS
J Mol Biol; 2013 Feb; 425(4):803-11. PubMed ID: 23219464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
